At Boehringer Ingelheim, we make a generational commitment to transforming cancer care. We are taking a diligent and broad approach in some of the most challenging, but potentially most impactful, areas of cancer research. Our goal is to transform the lives of people with cancer by delivering meaningful advances in areas of high unmet need. Dedifferentiated liposarcoma, or DDLPS, is a rare and aggressive form of sarcoma with a poor prognosis. Patients impacted by this devastating cancer have had no new first-line treatment options in 45 years. Boehringer Ingelheim’s Brightline-1 clinical trial is a Phase II/III randomized study of our investigational MDM2-p53 antagonist BI 907828 compared to doxorubicin as a first-line treatment for patients with advanced DDLPS. Brightline-1 is currently enrolling, with over 300 patients planned for enrollment in over 130 sites across Europe, the Asia-Pacific Region, and North America.
Boehringer Ingelheim